Halozyme Therapeutics, Inc. (HALO) Misses Q4 EPS by 3c; Roche (RHHBY) Triggers $4M Milestone
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $69.62 +0.91%
EPS Growth %: +17.5%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +17.5%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q4 EPS of ($0.18), $0.03 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $2.41 million versus the consensus estimate of $5.25 million.
Roche (OTCBB: RHHBY) submission trigger $4 million milestone payment.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Roche (OTCBB: RHHBY) submission trigger $4 million milestone payment.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- BofA lists top 5 themes driving next $1tn in incremental semi sales
- Tutor Perini prices $400M in senior notes to refinance debt
Create E-mail Alert Related Categories
Corporate News, Earnings, FDARelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
